Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosus of the vulva

Dermatology

Volumn 223, Issue 2, 2011, Pages 152-160

  Schwegler, J ^a   Schwarz, J ^a   Eulenburg, C ^b   Blome, C ^c   Ihnen, M ^a   Mahner, S ^a   Jaenicke, F ^a   Augustin, M ^a,c   Woelber, L ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Medical Biometry and Epidemiology ^*  (Germany)

^c Institute for Health Services Research in Dermatology and Nursing   (Germany)

Author keywords

Glucocorticosteroids; Lichen sclerosus; Patient Benefit Index; Quality of life; Skindex

Indexed keywords

CLOBETASOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EMOTIONAL STRESS; FEMALE; HUMAN; LICHEN SCLEROSUS ET ATROPHICUS; MAJOR CLINICAL STUDY; PATIENT BENEFIT INDEX; PRIORITY JOURNAL; QUALITY OF LIFE; SKINDEX 29; SOCIAL INTERACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; CLOBETASOL; EMOTIONS; FEMALE; HUMANS; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL PARTICIPATION; VULVAR LICHEN SCLEROSUS; YOUNG ADULT;

EID: 82455208991     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000332831     Document Type: Article

References (47)

1. Murphy R: Lichen sclerosus. Dermatol Clin 2010; 28: 707-715.
2. Eberz B, Berghold A, Regauer S: High prevalence of concomitant anogenital lichen sclerosus and extragenital psoriasis in adult women. Obstet Gynecol 2008; 111: 1143-1147. (Pubitemid 351620349)
3. Goldstein AT, Marinoff SC, Christopher K, Srodon M: Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med 2005; 50: 477-480. (Pubitemid 41022264)
4. Powell J, Wojnarowska F: Lichen sclerosus. Lancet 1999; 353: 1777-1783. (Pubitemid 29240387)
5. Reid R, Greenberg MD, Daoud Y, Husain M, Selvaggi S, Wilkinson E: Colposcopic findings in women with vulvar pain syndromes. A preliminary report. J Reprod Med 1988; 33: 523-532.
6. Meffert JJ, Davis BM, Grimwood RE: Lichen sclerosus. J Am Acad Dermatol 1995; 32: 393-416, quiz 417-418.
7. Gao XH, Barnardo MC, Winsey S, Ahmad T, Cook J, Agudelo JD, Zhai N, Powell JJ, Fuggle SV, Wojnarowska F: The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/ 03haplotype protects from vulval lichen sclerosus. J Invest Dermatol 2005; 125: 895-899.
8. Gross T, Wagner A, Ugurel S, Tilgen W, Reinhold U: Identification of Tia-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus. Dermatology 2001; 202: 198-202. (Pubitemid 32506965)
9. Farrell AM, Dean D, Millard PR, Charnock FM, Wojnarowska F: Cytokine alterations in lichen sclerosus: An immunohistochemical study. Br J Dermatol 2006; 155: 931-940. (Pubitemid 44564501)
10. Regauer S, Liegl B, Reich O, Beham-Schmid C: Vasculitis in lichen sclerosus: an under recognized feature? Histopathology 2004; 45: 237-244. (Pubitemid 39279180)
11. Hagedorn M, Goluke T, Mall G: Lichen sclerosus und Vulvakarzinom. J Dtsch Dermatol Ges 2003; 1: 864-868. (Pubitemid 37489882)
12. Küng F: Lichen sclerosus - hormonelle Therapie heute. Gynäkol Geburtshilfliche Rundsch 2000; 40: 29-32. (Pubitemid 30428557)
13. Cooper SM, Gao XH, Powell JJ, Wojnarowska F: Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol 2004; 140: 702-706. (Pubitemid 38747286)
14. Bracco GL, Carli P, Sonni L, Maestrini G, De Marco A, Taddei GL, Cattaneo A: Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J Reprod Med 1993; 38: 37-40. (Pubitemid 23049735)
15. Augustin M, Amon U, Bullinger M, Gieler U: Empfehlungen zur Erfassung der Lebensqualität in der Dermatologie. Dermatol Psychosom 2000; 1: 76-82.
16. Blome C, Maares J, Diepgen T, Jeffrustenbach S, Augustin M: Measurement of patient-relevant benefits in the treatment of chronic hand eczema - a novel approach. Contact Dermatitis 2009; 61: 39-45.
17. Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schafer I, Reusch M, Mielke V, Rustenbach SJ: The Patient Benefit Index: A novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 2009; 301: 561-571.
18. Zschocke I, Hammelmann U, Augustin M: Therapeutischer Nutzen in der dermatologischen Behandlung. Hautarzt 2005; 56: 839-846.
19. Schäfer R, Reich C, Augustin M: Quantitative Nutzenbewertung aus Patientensicht - der Patient Benefit Index (PBI). Kongress Medizin und Gesellschaft, Augsburg, 17-21 September 2007, German Medical Science GMS Publishing House; 2007 Doc 07 gmds 676 2007.
20. Zentner A, Velasco-Garrido M, Busse R: Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Bericht Nr 122 Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) 2005; GMS Health Technol Assess 1: Doc 09.
21. Berglund NL, Rylander E: Vulvar pain, sexual behavior and genital infections in a young population: a pilot study. Acta Obstet Gynecol Scand 2002; 81: 738-742. (Pubitemid 34953704)
22. Lamont J, Randazzo J, Farad M, Wilkins A, Daya D: Psychosexual and social profiles of women with vulvodynia. J Sex Marital Ther 2001; 27: 551-555. (Pubitemid 32802790)
23. Reed BD, Haefner HK, Punch MR, Roth RS, Gorenflo DW, Gillespie BW: Psychosocial and sexual functioning in women with vulvodynia and chronic pelvic pain. A comparative evaluation. J Reprod Med 2000; 45: 624-632. (Pubitemid 30661119)
24. Sadownik L: Clinical profile of vulvodynia patients. A prospective study of 300 patients. J Reprod Med 2000; 45: 679-684. (Pubitemid 30661128)
25. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ: Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713. (Pubitemid 26371086)
26. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ: Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440. (Pubitemid 27490569)
27. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J, Gieler U: German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology 2004; 209: 14-20. (Pubitemid 39179100)
28. Ponte M, Klemperer E, Sahay A, Chren MM: Effects of vulvodynia on quality of life. J Am Acad Dermatol 2009; 60: 70-76.
29. Schmidt S, Bauer A, Greif C, Merker A, Elsner P, Strauss B: Vulvar pain. Psychological profiles and treatment responses. J Reprod Med 2001; 46: 377-384. (Pubitemid 32428785)
30. Nijsten T, Sampogna F, Abeni D: Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009; 218: 151-154.
31. Nijsten TE, Sampogna F, Chren MM, Abeni DD: Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 1244-1250. (Pubitemid 43997903)
32. Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ: Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges 2008; 6: 113-120. (Pubitemid 351229573)
33. Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, Stander S: Measuring patientrelevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 2009; 161: 1143-1148.
34. Augustin M, Schafer I, Rabini S, Lee-Seifert C, Radtke M, Rustenbach SJ: Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit. Dermatology 2009; 218: 255-259.
35. Bachmann GA, Rosen R, Arnold LD, Burd I, Rhoads GG, Leiblum SR, Avis N: Chronic vulvar and other gynecologic pain: prevalence and characteristics in a self-reported survey. J Reprod Med 2006; 51: 3-9. (Pubitemid 43172811)
36. Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG: Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol 2006; 107: 617-624.
37. Jensen JT, Wilder K, Carr K, Romm J, Hansen A: Quality of life and sexual function after evaluation and treatment at a referral center for vulvovaginal disorders. Am J Obstet Gynecol 2003;188:1629-1635; discussion 1635-1637.
38. Sargeant HA, O'Callaghan FV: The impact of chronic vulval pain on quality of life and psychosocial well-being. Aust N Z J Obstet Gynaecol 2007; 47: 235-239. (Pubitemid 46909305)
39. Bullinger M: Methodische Grundlagen und Aspekte der Lebensqualität. Dtsch Med Wochenschr 2006; 131(19 suppl 1):S5-S7.
40. Marini A, Blecken S, Ruzicka T, Hengge UR: Lichen sclerosus. Neues zur Pathogenese und Therapie. Hautarzt 2005; 56: 550-555. (Pubitemid 40933243)
41. Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I: Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology 2008; 217: 101-106.
42. Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, Brinkmeier T, Frosch P, Moll I, Fritsch P, Muller K, Meykadeh N, Marini A, Ruzicka T, Gollnick H: Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006; 155: 1021-1028. (Pubitemid 44564514)
43. Lorenz B, Kaufman RH, Kutzner SK: Lichen sclerosus. Therapy with clobetasol propionate. J Reprod Med 1998; 43: 790-794. (Pubitemid 28430693)
44. Bornstein J, Heifetz S, Kellner Y, Stolar Z, Abramovici H: Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus. Am J Obstet Gynecol 1998; 178: 80-84. (Pubitemid 28302799)
45. Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, Dubertret L: Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2004; 140: 709-712. (Pubitemid 38747287)
46. Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ: A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011; 64:e99-e104.
47. Neill SM, Lewis FM, Tatnall FM, Cox NH: British Association of Dermatologists' guidelines for the management of lichen sclerosus. Br J Dermatol 2010; 163: 672-682.